2023年5月3日

Mezzion制药-注重一种罕见疾病的医药公司最近宣布,它已获得近4000万美元基金FUEL-2,这是它确认3期临床试验以及未来的商业化和其他国家的监管机构提交包括欧洲。Mezzion现在想给市场带来JURVIGO (udenafil),这是一种高度选择性的,独特的,强有力的5型磷酸二酯酶抑制剂(PDE-5抑制剂)对特定使用估计全球70 k单心室先天性心脏病(SV-CHD) 12岁及以上患者经历Fontan手术减轻。Fontan患者的平均寿命是35 - 45,除了JURVIGO之外,没有其他当前几种药物进行临床开发针对Fontan患者人群。和在Fontan JURVIGO治疗的主要目的是1)提高运动能力,2)执行日常体育活动提高他们的能力以更少的努力,和3)可能改善他们的寿命和生活质量。加上另一个潜在的好处与JURVIGO治疗可能会放缓Fontan Fontan-associated肝病的进展的主题。这个投资是增加实收资本从BRV资本管理(试验项目的全球经济增长的投资平台)。在医疗领域,BRV资本投资于生物技术公司承诺可以根据分化主导全球市场的产品。+ BRV也进行了成功的投资/退出到圣制药和Arvelle疗法。主要引用了:“我们已经获得稳定所需的资金和积极进步FUEL-2和提交包括欧洲其他国家的监管当局。我们FUEL-2协议提交给FDA和与全球领先的作物将是有史以来最大的临床试验进行Fontan病人。 In addition, we are expanding on global partnerships with hospital systems, advocacy groups, provider networks, and industry leaders dedicated to improving outcomes for those with SV-CHD. Our hope is that by continuing to invest in and support the Fontan patients, others will be inspired to do the same.” — Founder and CEO Dong-Hyun Park “BRV Capital participated in the Cardiology Conference by Children’s Hospital of Philadelphia (CHOP) in Puerto Rico at the end of February of this year and met many doctors and heart disease related professionals in person as part of its diligence effort. And also, we’ve been thoroughly reviewing Mezzion’s FUEL-1 data and the U.S. FDA’s response letters and comments carefully for a long time. As a result, the possibility of new drug approval based on the FUEL-2 Protocol was evaluated very high, so the head office decided to invest in Mezzion.” “The future market value was estimated considering attainable drug price after commercialization. BRV, as an institutional investor that focuses not on short-term profits, but on differentiated technology-based investments that can substantially grow, we would like to provide support from the new drug approval of udenafil to the success of global commercialization with strong partnership. We also subscribe to Mezzion’s corporate philosophy of helping all the patients around the World who are suffering from congenital diseases to open-up a new life.” — Yoon Kwan, CIO of BRV Capital Trending on Pulse 2.0